Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
Date:5/9/2011

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the first quarter ended March 31, 2011.

"Results from our recently completed Phase 2b study of lesinurad in combination with allopurinol demonstrate lesinurad's potential to bring relief to millions of patients currently suffering with gout," commented Barry D. Quart, PharmD, Ardea's president and chief executive officer.  "We look forward to presenting additional results from this study at the Annual European Congress of Rheumatology in May and discussing our plans for Phase 3 with the Food and Drug Administration in the third quarter."

Recent Accomplishments and Important Upcoming Events

  • In January 2011, we announced positive, topline results from a Phase 2b study (Study 203) adding lesinurad to allopurinol in 208 allopurinol-refractory patients.  At the highest lesinurad dose tested in this study, the number of patients taking the combination who achieved the medically recommended target of below 6 mg/dL was more than three times the number of patients who achieved the target on allopurinol alone.  This translated into an overall response rate of 89 percent using a "last observation carried forward", or LOCF, analysis.  The combination of lesinurad and allopurinol was also well tolerated.
  • In February 2011, we completed an underwritten public offering of approximately 3.2 million shares of our common stock, including the full exercise of an overallotment option granted to the underwriters.  Net proceeds from the sale of the shares, after deducting underwriting discounts and commissions and offering expenses, were approximately $78.1 million.
  • I
    '/>"/>

  • SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
    2. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
    3. Ardea Biosciences Prices Public Offering of Common Stock
    4. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
    5. Ardea Biosciences to Present at Two Upcoming Investor Conferences
    6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    8. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
    9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
    10. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
    11. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/15/2014)... Calif. , Sept. 15, 2014 ... new viral transport solution for safe ambient temperature ... to molecular testing. Importantly, the infectivity of agents in ... while maintaining the integrity of the viral nucleic ... of the recent Ebola epidemic in ...
    (Date:9/15/2014)... CA (PRWEB) September 15, 2014 ... term implantable silicones for the medical device and ... silicone gel for the implantable medical device market. ... unique crosslink technology delivering a silicone gel with ... The Dual Matrix technology consists of two crosslinked ...
    (Date:9/15/2014)... Sept. 15, 2014  The second annual International ... 12-18. A joint initiative of the Plasma Protein ... , IPAW is designed to: , Raise ... the contributions of plasma donors in saving and improving ... therapies and rare diseases Member companies ...
    (Date:9/14/2014)... survival strategies. They often create a biofilm to protect ... with antibiotics. A biofilm is a bacterial community that ... sugar chains and "curli". Scientists at VIB and ... a detailed three-dimensional image of the pores through which ... a crucial step in the formation of the protective ...
    Breaking Biology Technology:Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3New insights in survival strategies of bacteria 2
    ... , DURHAM, N.C., Aug. 12 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... 10-K for the fiscal year ended April 30, 2009. In addition to being available ... v , the 10-K can be downloaded from the company website at ... the Investors page. , , For the year ended April 30, ...
    ... , , LYNBROOK, N.Y., Aug. 12 ... company developing first in class collagenase-based products, today announced its ... , , "We were very pleased ... with Priority Review for XIAFLEX(TM) for the treatment of Dupuytren,s ...
    ... , , SAN DIEGO, Aug. 12 ... results for the three and six months ended June 30, 2009. , ... have the capital to complete and submit a New Drug Application (NDA) ... said Brian M. Culley, Principal Executive Officer at ADVENTRX. "Our financial ...
    Cached Biology Technology:Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 2Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 2ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 3ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 4ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 5ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 7
    (Date:9/15/2014)... week,s print issue of the journal Science ... New Mexico, Montana and even the Netherlands, thanks to ... more the norm in these connected times. Yes, the ... produce innovations in biology, medicine, biotechnology and agriculture. It ... talked with that one, that one knew another one, ...
    (Date:9/15/2014)... leading coral reef ecologists fears that reef biodiversity may ... that we once thought. , In an international study ... of Excellence for Coral Reef Studies (Coral CoE) says ... species within reef ecosystems. , In coral reefs, just ... that keep the ecosystem safe and functioning. , ...
    (Date:9/15/2014)... new strategic vision document, released today by the ... the long-term goals, objectives, and strategies for the ... over the next five years (2015-2020). In ... activities, to be funded in 2015, will include ... fellowships. , The $500 million, 30-year program ...
    Breaking Biology News(10 mins):Collaboration drives achievement in protein structure research 2Specialized species critical for reefs 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
    ... , , , , , , , ... , , , ... file available on request).,This noisy frog is a potent... , Click here for more ... , , , , , , ...
    ... with obese children shows that all diets are effective in ... one that accounts for how many carbs are in the ... glucose levels may be most promising. The Cincinnati ... and portion-controlled diets with obese children is published online in ...
    ... team has identified epigenetic signatures, markers on DNA that ... cells. These signatures can predict the expression of a ... stem cells (iPSCs), cells that take on embryonic stem ... is controlled brings us one step closer to developing ...
    Cached Biology News:Common North American frog identified as carrier of deadly amphibian disease 2Common North American frog identified as carrier of deadly amphibian disease 3Common North American frog identified as carrier of deadly amphibian disease 4New study compares diets for weight management in obese children 2Epigenetic signatures direct the repair potential of reprogrammed cells 2
    Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
    Mouse monoclonal antibody to RNase L...
    Compact, portable device, seals 96 and 384 well plates with preset temperature optimised for Eppendorf heat sealing foils and films. Suitable for plates of different heights. AC input: 50/60 Hz230 V...
    ... Caliper is proud to work in ... Automation Certified 25mm syringe filters in a ... filters are licensed for use on the ... Detailed Specifications and Pricing for our Automation ...
    Biology Products: